Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00282

Submission Number:
00282
Commenter:
Nirmit Patel
State:
New Jersey
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
CVS And Aetna Merger Mergers between PBM and plans is a huge threat to pharmacy industry. For those people who have spent endless hours in long lines at CVS stores, trying to figure out how to meditate while standing, this merger is bad news. It means, increasingly, they're going to be forced into those long lines. CVS doesn't win points on service, and it's these kind of vertical relationships that raise prices, and deny choices for consumers PBM mergers will create monopoly in market and less competition. This merger will lead to more narrow network, leading to increase in cost for the patient. CVS already owns Caremark and we have already seen what it has done to patient's right to chose pharmacy and poor quality of service at CVS pharmacy. This merger will ultimately do more harm to patient care.